A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers

Trial Profile

A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Apatorsen (Primary) ; Carboplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms Cedar; Spruce-2
  • Most Recent Events

    • 27 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Dec 2015 According to an OncoGenex Pharmaceuticals media release, progression-free survival results from this trial are expected in the first quarter of 2016 with continued overall survival follow up.
    • 04 Dec 2015 Accrual to date is 41% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top